Status:

COMPLETED

Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte

Lead Sponsor:

Cutera Inc.

Conditions:

Poikiloderma of Civatte

Dyschromia

Eligibility:

All Genders

35-65 years

Phase:

NA

Brief Summary

This study will evaluate the safety and efficacy of the Excel V 532 nm KTP laser for the treatment of dyschromia of the neck and/or chest (poikiloderma of Civatte).

Eligibility Criteria

Inclusion

  • Fitzpatrick Skin Type I - III
  • Clinical diagnosis of poikiloderma of Civatte affecting the neck and/or chest
  • Willing to refrain from using topical corticosteroids, retinoids and bleaching agents on the treated area
  • Agree not to undergo any other procedure for the treatment of poikiloderma of Civatte during the study
  • Willing and able to read, understand and sign the Informed Consent Form
  • Willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions

Exclusion

  • Any laser treatment on neck and/or chest within 12 months
  • Any topical treatment on neck and/or chest within 6 months
  • Pregnant and/or breastfeeding
  • Infection, dermatitis or a rash in the treatment area
  • Suffering from significant concurrent illness, such as Diabetes Mellitus or pertinent neurological disorders
  • History of seizure disorders due to light, fibromyalgia, connective tissue disease, vitiligo, psoriasis, pigmentary disorders, keloid scarring, hypertrophic scarring or abnormal wound healing
  • History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications
  • Having a known anticoagulative condition or taking anticoagulation medications
  • History of diseases stimulated by heat, unless treatment is conducted following a prophylactic regimen
  • Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely)
  • History of radiation to the head, neck and/or upper chest
  • Undergoing systemic chemotherapy for the treatment of cancer
  • Systemic use of isotretinoin (Accutane®) within 6 months
  • Any use of gold therapy
  • Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study
  • Current smoker or history of smoking within 12 months of study
  • Participation in a study of another device or drug within 6 months
  • As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in study

Key Trial Info

Start Date :

November 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT01491620

Start Date

November 1 2011

End Date

May 1 2013

Last Update

October 28 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zel Skin and Laser Specialists

Edina, Minnesota, United States, 55424